SRI 62-834

Subscribe to Selected New Research on SRI 62-834

5 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: related to ET-18-OCH(3); MLS-266-337 is (R(+))-isomer; structure given in first source

Also Known As:

(tetrahydro-2-(octadecycloxy)methylfuran-2-yl)methoxyphosphocholine; 2-((hydroxy-((2-((octadecyloxy)methyl)tetrahydrofuran-2-yl)methoxy)phosphinyl)oxy)-N,N,N-trimethylethylaminium hydroxide inner salt; CRC 86-05; MLS 266-337; MLS-266-337; NSC 614383; SDZ 266336, (S isomer); SDZ 266337, (R isomer); SRI 62834; SRI-62-834

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 02/01/1991 - "Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells." 12/01/1994 - "This compound was found to be as effective as ET-18-OCH3 and SRI 62-834, phospholipids with both strong direct and macrophage-induced cytotoxicity, in increasing survivors and reducing tumor volume when given either orally or intravenously in the mouse MethA fibrosarcoma model" Get all the results and reference details, order at left...
2.	Leukemia 06/01/1990 - "Incubation of SRI 62-834 with K562 erythroblastic leukemia cells also brought about a rise in the intracellular calcium" 02/01/1991 - "Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells." 06/01/1990 - "Incubation of 7.5 X 10(6)/ml HL-60 human myelomonocytic leukemia cells with between 10 and 50 microM SRI 62-834 brought about a concentration-dependent, biphasic rise in intracellular calcium, as measured by the calcium-sensitive fluorescent dye Quin-2 AM. Incubation with 30 microM SRI 62-834 elevated intracellular calcium from 110 to 415 nM after 10 min in a typical experiment; this concentration inhibited cell growth by greater than 90% (50% inhibition of growth was observed at 8 microM)" Get all the results and reference details, order at left...
3.	Multiple Sclerosis 04/01/1992 - "These results demonstrate the clear differences in the mode of action of these compounds in CR-EAE and suggest that SRI 62-834 could be an interesting candidate for the treatment of multiple sclerosis." Get all the results and reference details, order at left...
4.	Fibrosarcoma 12/01/1994 - "This compound was found to be as effective as ET-18-OCH3 and SRI 62-834, phospholipids with both strong direct and macrophage-induced cytotoxicity, in increasing survivors and reducing tumor volume when given either orally or intravenously in the mouse MethA fibrosarcoma model" Get all the results and reference details, order at left...
5.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 04/01/1992 - "The therapeutic effect of the ether phospholipid SRI 62-834, which lacks the characteristics of an immunosuppressive agent, was compared with those of two immunosuppressive drugs, cyclosporin and valine2-dihydrocyclosporin, in a rat model of chronic relapsing experimental allergic encephalomyelitis (CR-EAE)" 04/01/1992 - "SRI 62-834, a cyclic ether analogue of the phospholipid ET-18-OCH3, displays long-lasting beneficial effect in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat" Get all the results and reference details, order at left...
6 Diseases and 5 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Ethyl Ether (Ether)
2.	edelfosine
3.	Cyclosporine (Ciclosporin)
4.	Phospholipids
5.	Calcium
6.	Quin2
6 Drugs and Important Bio-Agents and 4 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>